Literature DB >> 11134526

Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways.

G H Xiao1, M Jeffers, A Bellacosa, Y Mitsuuchi, G F Vande Woude , J R Testa.   

Abstract

Hepatocyte growth factor (HGF) is a ligand of the receptor tyrosine kinase encoded by the c-Met protooncogene. HGF/Met signaling has multifunctional effects on various cell types. We sought to determine the role of HGF/Met in apoptosis and identify signal transducers involved in this process. In experiments with human SK-LMS-1 leiomyosarcoma cells, we show that the Akt kinase is activated by HGF in a time- and dose-dependent manner by phosphatidylinositol 3-kinase (PI3-kinase). Akt is also activated by active tumorigenic forms of Met, i.e., ligand-independent Tpr-Met, a truncated and constitutively dimerized form of Met, and a mutationally activated version of Met corresponding to that found in human hereditary papillary renal carcinoma. In NIH 3T3 cells transfected with wild-type Met, HGF inhibits apoptosis induced by serum starvation and UV irradiation. HGF-induced survival correlates with Akt activity and is inhibited by the specific PI3-kinase inhibitor LY294002, indicating that HGF inhibits cell death through the PI3-kinase/Akt signal transduction pathway. Furthermore, transiently transfected Tpr-Met activates Akt (both Akt1 and Akt2) and protects cells from apoptosis. Mitogen-activated protein kinase (MAPK) also is activated by HGF and rescues cells from apoptosis, although the cytoprotective effect is less marked than for PI3-kinase/Akt. Blocking MAPK with the specific MAPK kinase inhibitor PD098059 impairs the ability of HGF to promote cell survival. Similar results were obtained with NIH 3T3 cells expressing the fusion protein Trk-Met and stimulated with nerve growth factor, the Trk ligand. These results demonstrate that HGF/Met is capable of protecting cells from apoptosis by using both PI3-kinase/Akt and, to a lesser extent, MAPK pathways.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11134526      PMCID: PMC14576          DOI: 10.1073/pnas.98.1.247

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  38 in total

1.  Activating mutations for the met tyrosine kinase receptor in human cancer.

Authors:  M Jeffers; L Schmidt; N Nakaigawa; C P Webb; G Weirich; T Kishida; B Zbar; G F Vande Woude
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-14       Impact factor: 11.205

2.  Caspase activation is an early event in anthracycline-induced apoptosis and allows detection of apoptotic cells before they are ingested by phagocytes.

Authors:  F Durrieu; F Belloc; L Lacoste; P Dumain; J Chabrol; J Dachary-Prigent; H Morjani; M R Boisseau; J Reiffers; P Bernard; F Lacombe
Journal:  Exp Cell Res       Date:  1998-05-01       Impact factor: 3.905

3.  Transduction of interleukin-2 antiapoptotic and proliferative signals via Akt protein kinase.

Authors:  N N Ahmed; H L Grimes; A Bellacosa; T O Chan; P N Tsichlis
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

4.  Immunohistochemical analysis of hepatocyte growth factor in human coronary atherectomy specimens: comparison with transforming growth factor beta isoforms.

Authors:  H Ueda; M Imazu; Y Hayashi; K Ono; W Yasui; M Yamakido
Journal:  Virchows Arch       Date:  1997-05       Impact factor: 4.064

5.  Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas.

Authors:  L Schmidt; F M Duh; F Chen; T Kishida; G Glenn; P Choyke; S W Scherer; Z Zhuang; I Lubensky; M Dean; R Allikmets; A Chidambaram; U R Bergerheim; J T Feltis; C Casadevall; A Zamarron; M Bernues; S Richard; C J Lips; M M Walther; L C Tsui; L Geil; M L Orcutt; T Stackhouse; J Lipan; L Slife; H Brauch; J Decker; G Niehans; M D Hughson; H Moch; S Storkel; M I Lerman; W M Linehan; B Zbar
Journal:  Nat Genet       Date:  1997-05       Impact factor: 38.330

6.  Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt.

Authors:  L del Peso; M González-García; C Page; R Herrera; G Nuñez
Journal:  Science       Date:  1997-10-24       Impact factor: 47.728

7.  Regulation of neuronal survival by the serine-threonine protein kinase Akt.

Authors:  H Dudek; S R Datta; T F Franke; M J Birnbaum; R Yao; G M Cooper; R A Segal; D R Kaplan; M E Greenberg
Journal:  Science       Date:  1997-01-31       Impact factor: 47.728

Review 8.  Ras signalling and apoptosis.

Authors:  J Downward
Journal:  Curr Opin Genet Dev       Date:  1998-02       Impact factor: 5.578

9.  Hepatocyte growth factor/scatter factor-Met signaling induces proliferation, migration, and morphogenesis of pancreatic oval cells.

Authors:  M Jeffers; M S Rao; S Rulong; J K Reddy; V Subbarao; E Hudson; G F Vande Woude; J H Resau
Journal:  Cell Growth Differ       Date:  1996-12

10.  Activation of the 41/43 kDa mitogen-activated protein kinase signaling pathway is required for hepatocyte growth factor-induced cell scattering.

Authors:  S Tanimura; Y Chatani; R Hoshino; M Sato; S Watanabe; T Kataoka; T Nakamura; M Kohno
Journal:  Oncogene       Date:  1998-07-09       Impact factor: 9.867

View more
  115 in total

1.  Involvement of multiple signaling pathways in follicular lymphoma transformation: p38-mitogen-activated protein kinase as a target for therapy.

Authors:  Kojo S J Elenitoba-Johnson; Stephen D Jenson; Robert T Abbott; Robert A Palais; Sandra D Bohling; Zhaosheng Lin; Sheryl Tripp; Paul J Shami; Lai Y Wang; Robert W Coupland; Rena Buckstein; Bayardo Perez-Ordonez; Sherrie L Perkins; Ian D Dube; Megan S Lim
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-19       Impact factor: 11.205

Review 2.  Mechanisms of HGF/Met signaling to Brk and Sam68 in breast cancer progression.

Authors:  Alessia Locatelli; Kristopher A Lofgren; Andrea R Daniel; Nancy E Castro; Carol A Lange
Journal:  Horm Cancer       Date:  2012-04       Impact factor: 3.869

3.  An overview of the c-MET signaling pathway.

Authors:  Shawna Leslie Organ; Ming-Sound Tsao
Journal:  Ther Adv Med Oncol       Date:  2011-11       Impact factor: 8.168

4.  FAK, CD44v6, c-Met and EGFR in colorectal cancer parameters: tumour progression, metastasis, patient survival and receptor crosstalk.

Authors:  Alexandros Garouniatis; Adamantia Zizi-Sermpetzoglou; Spyros Rizos; Alkiviadis Kostakis; Nikolaos Nikiteas; Athanasios G Papavassiliou
Journal:  Int J Colorectal Dis       Date:  2012-06-26       Impact factor: 2.571

5.  Rutin as A Novel c-Met Inhibitory Lead for The Control of Triple Negative Breast Malignancies.

Authors:  Heba E Elsayed; Hassan Y Ebrahim; Mohamed M Mohyeldin; Abu Bakar Siddique; Amel M Kamal; Eman G Haggag; Khalid A El Sayed
Journal:  Nutr Cancer       Date:  2017-10-30       Impact factor: 2.900

Review 6.  Liver regeneration after partial hepatectomy: critical analysis of mechanistic dilemmas.

Authors:  George K Michalopoulos
Journal:  Am J Pathol       Date:  2009-12-17       Impact factor: 4.307

7.  Network inference using informative priors.

Authors:  Sach Mukherjee; Terence P Speed
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-17       Impact factor: 11.205

8.  HGF mediates cell proliferation of human mesothelioma cells through a PI3K/MEK5/Fra-1 pathway.

Authors:  Maria E Ramos-Nino; Steven R Blumen; Tara Sabo-Attwood; Harvey Pass; Michele Carbone; Joseph R Testa; Deborah A Altomare; Brooke T Mossman
Journal:  Am J Respir Cell Mol Biol       Date:  2007-09-13       Impact factor: 6.914

9.  Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair.

Authors:  Chang-Goo Huh; Valentina M Factor; Aránzazu Sánchez; Koichi Uchida; Elizabeth A Conner; Snorri S Thorgeirsson
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-30       Impact factor: 11.205

10.  Hepatocyte-specific c-Met deletion disrupts redox homeostasis and sensitizes to Fas-mediated apoptosis.

Authors:  Luis E Gómez-Quiroz; Valentina M Factor; Pal Kaposi-Novak; Cedric Coulouarn; Elizabeth A Conner; Snorri S Thorgeirsson
Journal:  J Biol Chem       Date:  2008-03-18       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.